Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Health Data Exchange topic

No spam. Unsubscribe anytime.

CalIndex interim CEO briefs board on statewide record plan; commissioners press on opt‑out and member notice

Health Service Board, City and County of San Francisco · November 10, 2016
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

CalIndex interim CEO Jerry Peters said the nonprofit is building a statewide longitudinal patient record and currently has payer participation from Anthem and Blue Shield; commissioners expressed concern about the program’s opt‑out enrollment and requested more detail on privacy, provider integration, and IRB safeguards for future research use.

Jerry (Gerry) Peters, interim CEO and general counsel of CalIndex, presented the organization’s purpose and progress: to create a consolidated longitudinal patient record for Californians so providers outside integrated systems can access clinically relevant history when treating patients.

Peters said CalIndex is a nonprofit aimed at advancing clinical research and care coordination and that the organization’s charter and policies prohibit selling data to commercial entities. He described progress to date: payer data from the Blues is in place and provider‑side integration (the clinical longitudinal patient record, or LPR) is moving into testing after two years of development. Peters said the current enrollment figure the group reports (about 9,500,000) comes primarily from payer data and that provider integration will expand that dataset over time.

Several commissioners raised concerns about notice and consent: earlier enrollment notifications were described as opt‑out (members automatically enrolled unless they read and actively opted out), and commissioners said many members were not given adequate prior notice. Commissioners also asked about research governance (IRB processes and data‑use protocols), data accuracy, provider incentives to contribute clinical data, and how member access to their own stored data would work.

Peters said CalIndex plans to comply with IRB requirements for research access, will seek to make data available to academic centers under clear rules, and apologized that prior outreach to some members could have been better timed. He committed to return with more detailed information and to meet additional board questions on governance, participation and timelines.

Board members did not take formal action and said they expect follow‑up presentations that clarify enrollment notice, data‑flow partners, governance and protections.